Illumina and Glaxosmithkline Sign Agreement For Large-Scale Genotyping Studies

26-Sep-2005

Illumina, Inc. announced that it has signed a commercial, multi-year, genotyping services agreement with GlaxoSmithKline (GSK). Under the terms of the agreement, Illumina will use Sentrix® Arrays in conjunction with the Company's GoldenGate® and Infinium(TM) assays to conduct genetic studies for thousands of samples provided by GSK. The blanket agreement enables multiple projects to be conducted over period of time.

Illumina has worked directly with GSK since June 2001, genotyping samples for a number of pharmacogenomics studies. The Company is providing no further detail.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...